semaglutide death and Cardiovascular Outcomes in Obesity without Diabetes Wegovy study: Semaglutide reduced risks

Even among patients with diabetes, where the clinical case for continued treatment was strongest, 46.5 percent stopped within 12 months

GLP-1 RAs have effects on both fasting and prandial blood glucose levels

If you are thinking about switching to Mounjaro, it is important to understand how the process will go

Accessed November 14, 2023

East Asia Market Insight : East Asia is increasingly focused on metabolic health and weight loss, with a growing interest in GLP-1 boosters as part of a comprehensive health regimen

Stop juggling multiple supplements that may contain high FODMAP ingredients that ferment and cause discomfort